Benzinga | Apr 28, 2021 04:15PM EDT

Apellis Pharmaceuticals Q1 EPS $(2.32) Misses $(1.62) Estimate

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(1.62) by 43.21 percent. This is a 1.31 percent decrease over losses of $(2.29) per share from the same period last year.